Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration

Abstract

A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol.

Description

[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 271,009, filed Jul. 15, 2009, U.S. Provisional Application No. 61 / 271,340, filed Jul. 20, 2009 and U.S. Provisional Application No. 61 / 337,011, filed Jan. 29, 2010. The contents of which are hereby incorporated by reference in their entirety.[0002]Throughout this application various publications are referenced by Arabic numeral in parentheses. The full citation the corresponding reference appears at the end of the specification before the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.BACKGROUND OF THE INVENTION[0003]Multiple sclerosis (MS) is a chronic, debilitating disease of the central nervous system (CNS) with either relapsing-remitting (RR) or progressive course leading to neurologic deterioration and disability. At time of initial diag...

AI Technical Summary

Benefits of technology

This patent describes a method for reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS) or those who have experienced a first clinical episode consistent with multiple sclerosis (MS) and have at least one lesion consistent with MS. The method involves administering a subcutaneous injection of a pharmaceutical solution containing glatiramer acetate and mannitol. The invention also includes a device for assisting in the injection process and a pre-filled syringe for use in the treatment. The technical effect of the invention is to reduce the frequency of relapses in patients with RRMS or those who have experienced a first clinical episode consistent with MS.

Problems solved by technology

Most of them are considered to act as immunomodulators but their mechanisms of action have not been completely elucidated.

As a result, GA can block the activation of myelin-reactive T cells or render these cells anergic.

Reducing the number and / or severity of the injection-site reactions in order to promote compliance and improving the quality of life for the patient remains a problem with GA treatment.

However, for a drug product composed of peptides and whose mechanism of action is not understood, the effects of any modification cannot be readily predicted.

Modifications of the formulation may unpredictably affect efficacy.

This alone is a significant problem when dealing with peptides of low solubility such as glatiramer acetate which is described as “sparingly soluble” (27).

Furthermore, concentrated polypeptide solutions are prone to additional problems.

Such formulations suffer from poor shelf-life, unacceptable turbidity, changes in pH, chemical degradation including hydrolysis and aggregation (both reversible and irreversible) and increases in viscosity; all of which potentially reduce shelf-life and bioavailability (25).

As a result, drugs delivered in a concentrated form to the interstitial space may be susceptible to enzymatic degradation at the injection site, precipitation and / or aggregation in the interstitial fluid, and endocytic / phagocytic mechanisms (26).

Images